Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this -
https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
Phase of development
Approved
Pre-registration & Phase III
Phase II & Phase II/III
Type of molecule
Cell and gene therapies
Monoclonal antibodies
Proteins
Peptides (recombinant)
Vaccines
Others
Target therapeutic area
Autoimmune disorders
Blood disorders
Bone disorders
Genetic disorders
Metabolic disorders
Neurological disorders
Oncological disorders
Respiratory disorders
Others
Type of drug delivery system
Large volume wearable injectors
Autoinjectors
Prefilled syringes
Needle-free injectors
Drug reconstitution systems
To Request for sample -
https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.
To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html
The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:
Phase of development
Approved
Pre-registration & Phase III
Phase II & Phase II/III
Type of molecule
Cell and gene therapies
Monoclonal antibodies
Proteins
Peptides (recombinant)
Vaccines
Others
Target therapeutic area
Autoimmune disorders
Blood disorders
Bone disorders
Genetic disorders
Metabolic disorders
Neurological disorders
Oncological disorders
Respiratory disorders
Others
Type of drug delivery system
Large volume wearable injectors
Autoinjectors
Prefilled syringes
Needle-free injectors
Drug reconstitution systems
To Request for sample - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html